Hudbay Completes Transaction to Consolidate 100% Ownership in the Copper Mountain Mine
TORONTO, April 30, 2025 (GLOBE NEWSWIRE) — Hudbay Minerals Inc. (“Hudbay” or the “Company”) (TSX, NYSE: HBM) is pleased to […]
Sun Communities, Inc. Completes Sale of Safe Harbor Marinas to Blackstone Infrastructure
Southfield, MI, April 30, 2025 (GLOBE NEWSWIRE) — Sun Communities, Inc. (NYSE: SUI) (the “Company” or “Sun”), a real estate investment […]
Teladoc Health Acquires UpLift, Expanding Consumer Access to Mental Health Care Services Through Covered Benefits
PURCHASE, NY, April 30, 2025 (GLOBE NEWSWIRE) — Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced […]
Toll Brothers Opens New Luxury Townhome Community, Marker Ridge, in Irvington, New York
IRVINGTON, N.Y., April 30, 2025 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced […]
TSX News -
Calian to Hold Conference Call Following Announcement of Second Quarter FY 2025 Results
OTTAWA, Ontario, April 30, 2025 (GLOBE NEWSWIRE) — Calian® Group Ltd. (TSX:CGY), a diverse products and services company providing innovative […]
HII Launching New “Build It: In America, For America” Ads Celebrating U.S.-based Manufacturing Work and Workforce
NEWPORT NEWS, Va., April 30, 2025 (GLOBE NEWSWIRE) — HII (NYSE: HII), America’s largest military shipbuilder, is launching a series […]
BioSyent to Present at 2025 Bloom Burton & Co. Healthcare Investor Conference
MISSISSAUGA, Ontario, April 30, 2025 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it […]
LNG Energy Group Announces Director and Officer Resignation
TORONTO, April 30, 2025 (GLOBE NEWSWIRE) — LNG Energy Group Corp. (TSXV: LNGE) (TSXV: LNGE.WT) (OTCQB: LNGNF) (FRA: E26) (the […]
FLUENT Expands KNACK Product Portfolio with Multipack Pre-Roll Launch in New York
NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) — FLUENT Corp. (CSE: FNT.U) (OTCQB: CNTMF) (“FLUENT” or the “Company”), a national […]
TSX News -
Medicenna Presents Promising Preclinical Data from its First-in-Class Tumor Targeted and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the Annual 2025 AACR Meeting
MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” anti-PD-1-IL-2 Superkine (anti-PD1-IL-2SK), engineered to precisely deliver clinically validated anti-PD1 and IL-2SKto […]
